Novo Nordisk rolls out long-awaited Tresiba, aiming for blockbuster market share

Tracy Staton Novo Nordisk finally launched its next-gen diabetes treatment Tresiba in the U.S., approved by the FDA last September. The Danish drugmaker has high hopes ...

Novo Nordisk strikes deal with Iran government to produce insulin pens in the country

Eric Palmer Novo Nordisk will step up its operations in Iran, saying today it will build a €70 million ($ 78.1 million) plant to produce its FlexPen prefilled devices to better ...

Novo Nordisk ties the R&D knot with Genmab, and they’re not focused on cancer

John Carroll Novo Nordisk is jumping on Genmab's antibody development platform in search of two new drug programs–and this time the Danish biotech company will not be focused ...

Novo Nordisk launches diabetes ‘dream team’ contest with NBA star as a prize

Carly Helfand Former NBA star Dominique Wilkins is not just a spokesman for Novo Nordisk's Victoza. He's also a prize in a Type 2 diabetes sweepstakes the drugmaker is rolling ...

Novo Nordisk backs out of a diabetes deal with Zosano

Damian Garde Novo Nordisk has terminated a collaboration deal with Zosano Pharma, walking away from an agreement that would have paired its late-stage diabetes drug with the latter ...

Novo Nordisk quells diabetes pricing fears with 2015 growth forecast

Tracy Staton Novo Nordisk has made diabetes-minded investors very happy today. Rather than following Sanofi's discouraging announcement of flat sales expectations in the field next ...

Novo Nordisk bets another $130M on diabetes R&D with new Danish hub

Damian Garde Novo Nordisk has broken ground on a new R&D shop in its native Denmark, plotting a $ 130 million project that will expand its wide footprint in diabetes research. FierceBiotech ...

Novo Nordisk picks diabetes-ridden Mexico for first Ryzodeg launch

Tracy Staton Earlier this year, Novo Nordisk said it would target Mexico as its next market for an obesity-fighting formula of liraglutide, sold for diabetes as Victoza. Now, the company ...

Novo Nordisk eyes IPO for its IT subsidiary, taps new CFO to lead review

Tracy Staton Strategic reviews, sales and spinoffs are trendy in Big Pharma these days. Now, the Danish drugmaker Novo Nordisk has joined the bunch. Novo says it's weighing an initial ...

Drug buyers sue Novo Nordisk over ‘wrongful’ delays to diabetes generic

Carly Helfand The Federal Trade Commission may now have the right to challenge pay-for-delay deals, but drugmakers can still stall the launches of competing generic products. And that's ...

China Probes Novo Nordisk

mia.burns Chinese authorities have visited a site operated by Danish drugmaker Novo Nordisk, the world’s biggest maker of insulin, in the latest sign of a widening investigation ...

FDA deals Novo Nordisk another setback for hemophilia therapy

Ryan McBride The FDA has delivered a second complete response to the Danish drugmaker for its recombinant Factor VIII therapy, BioCentury reported, citing unresolved findings at the ...
Page 1 of 212
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS